Non-Hodgkin Lymphoma | Tumor

CURE’s non-Hodgkin lymphoma (NHL) page is an extensive resource of cancer information featuring the latest NHL news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on non-Hodgkin lymphoma.

Diagnosing Asymptomatic Cancer With Blood Tests Could Save Lives

November 12th 2020, 10:00pm

Article

Finding cancer may be easier now, as blood tests are being developed to diagnose patients with asymptomatic cancer.

How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment

November 11th 2020, 7:00pm

Article

CAR-T cell therapy is a relatively new treatment option for patients with blood cancers, but it’s one showing promise across the landscape. Here’s what you need to know.

What’s New in Hodgkin Lymphoma: Expert Gives an Overview

November 6th 2020, 2:00pm

Article

Outcomes for patients with Hodgkin lymphoma continue to improve, thanks to new drugs, according to Dr. Pamela Allen.

Novel Targeted Drugs are Changing the Treatment of Diffuse Large B-Cell Lymphoma

November 5th 2020, 2:00pm

Article

Three targeted drugs have recently been approved to treat diffuse large B-cell lymphoma, broadening the treatment options for patients with this aggressive blood cancer, according to Dr. Germame Ajebo.

Abbreviated Treatment Improves Quality of Life and Appears Safe in Some with Diffuse Large B Cell Lymphoma

October 29th 2020, 9:00pm

Article

Giving fewer courses of chemotherapy and no radiation could become a new standard for patients with stage 1 or 2 diffuse large B cell lymphoma based on the results of a recent study.

CAR-T Cell Therapy Side Effects: Know What to Look Out For

October 20th 2020, 1:00pm

Article

CAR-T cell therapy is drastically improving outcomes for patients with diffuse large B-cell lymphoma. However, the treatment can come with some severe side effects that patients need to know about.

New CAR-T Cell Therapy, Given with Keytruda, Is Safe and Effective in Treating Diffuse Large B Cell Lymphoma

October 13th 2020, 1:00pm

Article

Combining the immunotherapy Keytruda with a CAR-T cell therapy that targets the proteins CD19 and CD22 generates complete responses with minimal side effects, results from an early study demonstrate.

What Certain Patients with DLBCL Need To Know About Monjuvi-Revlimid

September 14th 2020, 3:00pm

Video

Patients with relapsed/refractory diffuse large B-cell lymphoma who are unable to undergo autologous stem cell transplant have a new treatment option in the combination of Monjuvi and Revlimid. The lead researcher on the study that led to the combination’s approval discusses what patients need to know.

Monjuvi-Revlimid Combination Approval Fills Unmet Need for Certain Patients with DLBCL

September 4th 2020, 6:00pm

Article

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Intensifying Rituxan for Diffuse Large B-Cell Lymphoma Treatment Does Not Improve Health Outcomes

September 2nd 2020, 9:00pm

Article

Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.